Top

Published in:

01-12-2011

The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis

Authors: Prasanna Ekambaram, Wanyu Lambiv, Rosanna Cazzolli, Anthony W. Ashton, Kenneth V. Honn

Published in: Cancer and Metastasis Reviews | Issue 3-4/2011

Abstract

Thromboxane A₂ (TXA₂) is a biologically active metabolite of arachidonic acid formed by the action of the terminal synthase, thromboxane A₂ synthase (TXA₂S), on prostaglandin endoperoxide (PGH₂). TXA₂ is responsible for multiple biological processes through its cell surface receptor, the T-prostanoid (TP) receptor. Thromboxane A₂ synthase and TP are the two necessary components for the functioning of this potent bioactive lipid. Thromboxane A₂ is widely implicated in a range of cardiovascular diseases, owing to its acute and chronic effects in promoting platelet aggregation, vasoconstriction, and proliferation. In recent years, additional functional roles for both TXA₂S and TP in cancer progression have been indicated. Increased cyclooxygenase (COX)-2 expression has been described in a variety of human cancers, which has focused attention on TXA₂ as a downstream metabolite of the COX-2-derived PGH₂. Several studies suggest potential involvement of TXA₂S and TP in tumor progression, especially tumor cell proliferation, migration, and invasion that are key steps in cancer progression. In addition, the regulation of neovascularization by TP has been identified as a potent source of control during oncogenesis. There have been several recent reviews of TXA₂S and TP but thus far none have discussed its role in cancer progression and metastasis in depth. This review will focus on some of the more recent findings and advances with a significant emphasis on understanding the functional role of TXA₂S and TP in cancer progression and metastasis.

Hamberg, M., Svensson, J., & Samuelsson, B. (1975). Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proceedings of the National Academy of Sciences of the United States of America, 72(8), 2994–2998.PubMed

Moncada, S., Needleman, P., Bunting, S., & Vane, J. R. (1976). Prostaglandin endoperoxide and thromboxane generating systems and their selective inhibition. Prostaglandins, 12(3), 323–335.PubMed

Smyth, E. M. (2010). Thromboxane and the thromboxane receptor in cardiovascular disease. Clinical Lipidology, 5(2), 209–219. doi:10.2217/clp.10.11.PubMed

Needleman, P., Minkes, M., & Raz, A. (1976). Thromboxanes: Selective biosynthesis and distinct biological properties. Science, 193(4248), 163–165.PubMed

Needleman, P., Moncada, S., Bunting, S., Vane, J. R., Hamberg, M., & Samuelsson, B. (1976). Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. Nature, 261(5561), 558–560.PubMed

Halushka, P. V., Allan, C. J., & Davis-Bruno, K. L. (1995). Thromboxane A2 receptors. Journal of Lipid Mediators and Cell Signalling, 12(2–3), 361–378.PubMed

Jones, R. L., Wilson, N. H., & Armstrong, R. A. (1985). Characterization of thromboxane receptors in human platelets. Advances in Experimental Medicine and Biology, 192, 67–81.PubMed

Fitzgerald, D. J., Roy, L., Catella, F., & FitzGerald, G. A. (1986). Platelet activation in unstable coronary disease. The New England Journal of Medicine, 315(16), 983–989. doi:10.1056/nejm198610163151602.PubMed

Katugampola, S. D., & Davenport, A. P. (2001). Thromboxane receptor density is increased in human cardiovascular disease with evidence for inhibition at therapeutic concentrations by the AT(1) receptor antagonist losartan. British Journal of Pharmacology, 134(7), 1385–1392. doi:10.1038/sj.bjp.0704416.PubMed

10.

Neri Serneri, G. G., Gensini, G. F., Abbate, R., Mugnaini, C., Favilla, S., Brunelli, C., et al. (1981). Increased fibrinopeptide A formation and thromboxane A2 production in patients with ischemic heart disease: Relationships to coronary pathoanatomy, risk factors, and clinical manifestations. American Heart Journal, 101(2), 185–194.PubMed

11.

Fuse, S., & Kamiya, T. (1994). Plasma thromboxane B2 concentration in pulmonary hypertension associated with congenital heart disease. Circulation, 90(6), 2952–2955.PubMed

12.

Gresele, P., Deckmyn, H., Nenci, G. G., & Vermylen, J. (1991). Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders. Trends in Pharmacological Sciences, 12(4), 158–163.PubMed

13.

Kobayashi, T., Tahara, Y., Matsumoto, M., Iguchi, M., Sano, H., Murayama, T., et al. (2004). Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. The Journal of Clinical Investigation, 114(6), 784–794. doi:10.1172/jci21446.PubMed

14.

Mehta, J. L., Lawson, D., Mehta, P., & Saldeen, T. (1988). Increased prostacyclin and thromboxane A2 biosynthesis in atherosclerosis. Proceedings of the National Academy of Sciences of the United States of America, 85(12), 4511–4515.PubMed

15.

Willerson, J. T., Yao, S. K., Ferguson, J. J., Anderson, H. V., Golino, P., & Buja, L. M. (1991). Unstable angina pectoris and the progression to acute myocardial infarction. Role of platelets and platelet-derived mediators. Texas Heart Institute Journal, 18(4), 243–247.PubMed

16.

Lariviere, R., Moreau, C., Rodrigue, M. E., & Lebel, M. (2004). Thromboxane blockade reduces blood pressure and progression of renal failure independent of endothelin-1 in uremic rats. Prostaglandins, Leukotrienes, and Essential Fatty Acids, 71(2), 103–109. doi:10.1016/j.plefa.2003.12.021.PubMed

17.

Willerson, J. T., & Buja, L. M. (1990). Potential of combined thromboxane A2 and serotonin antagonists to prevent the development of unstable angina and acute myocardial infarction. Texas Heart Institute Journal, 17(3), 157–164.PubMed

18.

Willerson, J. T., Golino, P., Eidt, J., Yao, S. K., & Buja, L. M. (1990). Potential usefulness of combined thromboxane A2 and serotonin receptor blockade for preventing the conversion from chronic to acute coronary artery disease syndromes. The American Journal of Cardiology, 66(16), 48G–53G.PubMed

19.

Haurand, M., & Ullrich, V. (1985). Isolation and characterization of thromboxane synthase from human platelets as a cytochrome P-450 enzyme. Journal of Biological Chemistry, 260(28), 15059–15067.PubMed

20.

Ohashi, K., Ruan, K. H., Kulmacz, R. J., Wu, K. K., & Wang, L. H. (1992). Primary structure of human thromboxane synthase determined from the cDNA sequence. Journal of Biological Chemistry, 267(2), 789–793.PubMed

21.

Shen, R. F., & Tai, H. H. (1998). Thromboxanes: Synthase and receptors. Journal of Biomedical Science, 5(3), 153–172.PubMed

22.

Yokoyama, C., Miyata, A., Ihara, H., Ullrich, V., & Tanabe, T. (1991). Molecular cloning of human platelet thromboxane A synthase. Biochemical and Biophysical Research Communications, 178(3), 1479–1484.PubMed

23.

Tanabe, T., & Ullrich, V. (1995). Prostacyclin and thromboxane synthases. Journal of Lipid Mediators and Cell Signalling, 12(2–3), 243–255.PubMed

24.

Hirata, M., Hayashi, Y., Ushikubi, F., Yokota, Y., Kageyama, R., Nakanishi, S., et al. (1991). Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature, 349(6310), 617–620. doi:10.1038/349617a0.PubMed

25.

Raychowdhury, M. K., Yukawa, M., Collins, L. J., McGrail, S. H., Kent, K. C., & Ware, J. A. (1994). Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane A2 receptor. Journal of Biological Chemistry, 269(30), 19256–19261 [Comparative Study].PubMed

26.

Kinsella, B. T. (2001). Thromboxane A2 signalling in humans: A 'Tail' of two receptors. Biochemical Society Transactions, 29(Pt 6), 641–654.PubMed

27.

Miggin, S. M., & Kinsella, B. T. (1998). Expression and tissue distribution of the mRNAs encoding the human thromboxane A2 receptor (TP) alpha and beta isoforms. Biochimica et Biophysica Acta, 1425(3), 543–559 [Research Support, Non-U.S. Gov't].PubMed

28.

Nakahata, N. (2008). Thromboxane A2: Physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacology and Therapeutics, 118(1), 18–35. doi:10.1016/j.pharmthera.2008.01.001.PubMed

29.

Namba, T., & Narumiya, S. (1993). Thromboxane A2 receptor; structure, function and tissue distribution. Nihon Rinsho, 51(1), 233–240.PubMed

30.

Honn, K. V., Bockman, R. S., & Marnett, L. J. (1981). Prostaglandins and cancer: A review of tumor initiation through tumor metastasis. Prostaglandins, 21(5), 833–864.PubMed

31.

Honn, K. V., Busse, W. D., & Sloane, B. F. (1983). Prostacyclin and thromboxanes. Implications for their role in tumor cell metastasis. Biochemical Pharmacology, 32(1), 1–11.PubMed

32.

Menter, D. G., Neagos, J., Dunn, R., Pallazo, T. T., Chen, T., Taylor, J. D. et al. (1982). Tumor Cell induced Platelet aggregration: Inhibition by prostacylin, thromboxane A2 and phosphodiesterase inhibitors. In T. J. Powles, R. S. Bockman, K. V.Honn, P. W. Ramwell (Ed.), Prostaglandins and cancer (pp. 369–374). New York: Alan Liss, Inc.

33.

Nie, D., & Honn, K. V. (2002). Cyclooxygenase, lipoxygenase and tumor angiogenesis. Cellular and Molecular Life Sciences, 59(5), 799–807.PubMed

34.

Honn, K. V., & Meyer, J. (1981). Thromboxanes and prostacyclin: Positive and negative modulators of tumor growth. Biochemical and Biophysical Research Communications, 102(4), 1122–1129.PubMed

35.

U.S.C.S.W.Group (2010). United States Cancer Statistics: 1999–2007 Incidence and Mortality Web-based Report: Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute.

36.

Bairati, I., Meyer, F., Fradet, Y., & Moore, L. (1998). Dietary fat and advanced prostate cancer. The Journal of Urology, 159(4), 1271–1275 [Research Support, Non-U.S. Gov't].PubMed

37.

Rose, D. P., & Connolly, J. M. (1992). Dietary fat, fatty acids and prostate cancer. Lipids, 27(10), 798–803 [Review].PubMed

38.

West, D. W., Slattery, M. L., Robison, L. M., French, T. K., & Mahoney, A. W. (1991). Adult dietary intake and prostate cancer risk in Utah: A case-control study with special emphasis on aggressive tumors. Cancer Causes & Control, 2(2), 85–94 [Research Support, U.S. Gov't, P.H.S.].

39.

Gupta, S., Srivastava, M., Ahmad, N., Sakamoto, K., Bostwick, D. G., & Mukhtar, H. (2001). Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. Cancer, 91(4), 737–743.PubMed

40.

Nie, D., Che, M., Grignon, D., Tang, K., & Honn, K. V. (2001). Role of eicosanoids in prostate cancer progression. Cancer Metastasis Reviews, 20(3–4), 195–206.PubMed

41.

Nie, D., Hillman, G. G., Geddes, T., Tang, K., Pierson, C., Grignon, D. J., et al. (1999). Platelet-type 12-lipoxygenase regulates angiogenesis in human prostate carcinoma. Advances in Experimental Medicine and Biology, 469, 623–630.PubMed

42.

Nie, D., Nemeth, J., Qiao, Y., Zacharek, A., Li, L., Hanna, K., et al. (2003). Increased metastatic potential in human prostate carcinoma cells by overexpression of arachidonate 12-lipoxygenase. Clinical & Experimental Metastasis, 20(7), 657–663.

43.

Gupta, S., Srivastava, M., Ahmad, N., Bostwick, D. G., & Mukhtar, H. (2000). Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. The Prostate, 42(1), 73–78.PubMed

44.

Lee, L. M., Pan, C. C., Cheng, C. J., Chi, C. W., & Liu, T. Y. (2001). Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia. Anticancer Research, 21, 1291–1294.PubMed

45.

Nie, D., Che, M., Zacharek, A., Qiao, Y., Li, L., Li, X., et al. (2004). Differential expression of thromboxane synthase in prostate carcinoma: Role in tumor cell motility. American Journal of Pathology, 164(2), 429–439. doi:10.1016/s0002-9440(10)63133-1.PubMed

46.

Dassesse, T., de Leval, X., de Leval, L., Pirotte, B., Castronovo, V., & Waltregny, D. (2006). Activation of the thromboxane A2 pathway in human prostate cancer correlates with tumor Gleason score and pathologic stage. Eur Urol, 50(5), 1021–1031; discussion 1031, doi:10.1016/j.eururo.2006.01.036.

47.

Villers, A., McNeal, J. E., Redwine, E. A., Freiha, F. S., & Stamey, T. A. (1989). The role of perineural space invasion in the local spread of prostatic adenocarcinoma. Journal of Urology, 142(3), 763–768.PubMed

48.

Pantel, K., & Brakenhoff, R. H. (2004). Dissecting the metastatic cascade. [Review]. Nature reviews. Cancer, 4(6), 448–456, doi:10.1038/nrc1370.

49.

Nie, D., Guo, Y., Yang, D., Tang, Y., Chen, Y., Wang, M. T., et al. (2008). Thromboxane A2 receptors in prostate carcinoma: Expression and its role in regulating cell motility via small GTPase Rho. Cancer Research, 68(1), 115–121. doi:10.1158/0008-5472.can-07-1018.PubMed

50.

Kelly, P., Stemmle, L. N., Madden, J. F., Fields, T. A., Daaka, Y., & Casey, P. J. (2006). A role for the G12 family of heterotrimeric G proteins in prostate cancer invasion. Journal of Biological Chemistry, 281(36), 26483–26490. doi:10.1074/jbc.M604376200.PubMed

51.

Turner, E. C., Kavanagh, D. J., Mulvaney, E. P., McLean, C., Wikstrom, K., Reid, H. M., et al. (2011). Identification of an interaction between the TPalpha and TPbeta isoforms of the human thromboxane A2 receptor with protein kinase C-related kinase (PRK) 1: Implications for prostate cancer. Journal of Biological Chemistry, 286(17), 15440–15457. doi:10.1074/jbc.M110.181180.PubMed

52.

Watkins, G., Douglas-Jones, A., Mansel, R. E., & Jiang, W. G. (2005). Expression of thromboxane synthase, TBXAS1 and the thromboxane A2 receptor, TBXA2R, in human breast cancer. International Seminars in Surgical Oncology, 2, 23. doi:10.1186/1477-7800-2-23.PubMed

53.

Kelly, P., Moeller, B. J., Juneja, J., Booden, M. A., Der, C. J., Daaka, Y., et al. (2006). The G12 family of heterotrimeric G proteins promotes breast cancer invasion and metastasis. Proceedings of the National Academy of Sciences of the United States of America, 103(21), 8173–8178. doi:10.1073/pnas.0510254103.PubMed

54.

Abraham, J. E., Harrington, P., Driver, K. E., Tyrer, J., Easton, D. F., Dunning, A. M., et al. (2009). Common polymorphisms in the prostaglandin pathway genes and their association with breast cancer susceptibility and survival. Clinical Cancer Research, 15(6), 2181–2191. doi:10.1158/1078-0432.CCR-08-0716.PubMed

55.

Ermert, L., Dierkes, C., & Ermert, M. (2003). Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors. Clinical Cancer Research, 9(5), 1604–1610.PubMed

56.

Kreutzer, M., Fauti, T., Kaddatz, K., Seifart, C., Neubauer, A., Schweer, H., et al. (2007). Specific components of prostanoid-signaling pathways are present in non-small cell lung cancer cells. Oncology Reports, 18(2), 497–501.PubMed

57.

Yoshimoto, A., Kasahara, K., Kawashima, A., Fujimura, M., & Nakao, S. (2005). Characterization of the prostaglandin biosynthetic pathway in non-small cell lung cancer: A comparison with small cell lung cancer and correlation with angiogenesis, angiogenic factors and metastases. Oncology Reports, 13(6), 1049–1057.PubMed

58.

Wei, J., Yan, W., Li, X., Ding, Y., & Tai, H. H. (2010). Thromboxane receptor alpha mediates tumor growth and angiogenesis via induction of vascular endothelial growth factor expression in human lung cancer cells. Lung Cancer, 69(1), 26–32. doi:10.1016/j.lungcan.2009.09.009.PubMed

59.

Wei, J., Yan, W., Li, X., Chang, W. C., & Tai, H. H. (2007). Activation of thromboxane receptor alpha induces expression of cyclooxygenase-2 through multiple signaling pathways in A549 human lung adenocarcinoma cells. Biochemical Pharmacology, 74(5), 787–800. doi:10.1016/j.bcp.2007.06.008.PubMed

60.

Li, X., & Tai, H. H. (2009). Activation of thromboxane A(2) receptors induces orphan nuclear receptor Nurr1 expression and stimulates cell proliferation in human lung cancer cells. Carcinogenesis, 30(9), 1606–1613. doi:10.1093/carcin/bgp161.PubMed

61.

Nie, D., Lamberti, M., Zacharek, A., Li, L., Szekeres, K., Tang, K., et al. (2000). Thromboxane A(2) regulation of endothelial cell migration, angiogenesis, and tumor metastasis. Biochemical and Biophysical Research Communications, 267(1), 245–251. doi:10.1006/bbrc.1999.1840.PubMed

62.

Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. Cell, 100(1), 57–70 [Review].PubMed

63.

Fujimura, M., Kasahara, K., Shirasaki, H., Heki, U., Iwasa, K., Ueda, A., et al. (1999). Up-regulation of ICH-1 L protein by thromboxane A2 antagonists enhances cisplatin-induced apoptosis in non-small-cell lung-cancer cell lines. Journal of Cancer Research and Clinical Oncology, 125(7), 389–394.PubMed

64.

Leung, K. C., Hsin, M. K., Chan, J. S., Yip, J. H., Li, M., Leung, B. C., et al. (2009). Inhibition of thromboxane synthase induces lung cancer cell death via increasing the nuclear p27. Experimental cell research, 315(17), 2974–2981. doi:10.1016/j.yexcr.2009.06.025 [Research Support, Non-U.S. Gov't].PubMed

65.

Leung, K. C., Li, M. Y., Leung, B. C., Hsin, M. K., Mok, T. S., Underwood, M. J., et al. (2010). Thromboxane synthase suppression induces lung cancer cell apoptosis via inhibiting NF-kappaB. Experimental Cell Research, 316(20), 3468–3477.PubMed

66.

McLemore, T. L., Hubbard, W. C., Litterst, C. L., Liu, M. C., Miller, S., McMahon, N. A., et al. (1988). Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients. Cancer Research, 48(11), 3140–3147.PubMed

67.

Huang, R. Y., Li, M. Y., Hsin, M. K., Underwood, M. J., Ma, L. T., Mok, T. S., et al. (2011). 4-Methylnitrosamino-1-3-pyridyl-1-butanone (NNK) promotes lung cancer cell survival by stimulating thromboxane A2 and its receptor. Oncogene, 30(1), 106–116. doi:10.1038/onc.2010.390 [Research Support, Non-U.S. Gov't].PubMed

68.

Cathcart, M. C., Gately, K., Cummins, R., Kay, E., O'Byrne, K. J., & Pidgeon, G. P. (2011). Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer. Molecular Cancer, 10, 25.PubMed

69.

McAfee, A. J., McSorley, E. M., Cuskelly, G. J., Moss, B. W., Wallace, J. M., Bonham, M. P., et al. (2010). Red meat consumption: An overview of the risks and benefits. Meat science, 84(1), 1–13.PubMed

70.

Bing, R. J., Miyataka, M., Rich, K. A., Hanson, N., Wang, X., Slosser, H. D., et al. (2001). Nitric oxide, prostanoids, cyclooxygenase, and angiogenesis in colon and breast cancer. Clinical Cancer Research, 7(11), 3385–3392.PubMed

71.

Tsujii, M., Kawano, S., & DuBois, R. N. (1997). Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proceedings of the National Academy of Sciences of the United States of America, 94(7), 3336–3340.PubMed

72.

Pradono, P., Tazawa, R., Maemondo, M., Tanaka, M., Usui, K., Saijo, Y., et al. (2002). Gene transfer of thromboxane A(2) synthase and prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Research, 62(1), 63–66.PubMed

73.

Gustafsson, A., Hansson, E., Kressner, U., Nordgren, S., Andersson, M., Lonnroth, C., et al. (2007). Prostanoid receptor expression in colorectal cancer related to tumor stage, differentiation and progression. Acta Oncologica, 46(8), 1107–1112. doi:10.1080/02841860701403061.PubMed

74.

Sakai, H., Suzuki, T., Takahashi, Y., Ukai, M., Tauchi, K., Fujii, T., et al. (2006). Upregulation of thromboxane synthase in human colorectal carcinoma and the cancer cell proliferation by thromboxane A2. FEBS Letters, 580(14), 3368–3374. doi:10.1016/j.febslet.2006.05.007.PubMed

75.

Sathornsumetee, S., & Rich, J. N. (2006). New treatment strategies for malignant gliomas. Expert Review of Anticancer Therapy, 6(7), 1087–1104. doi:10.1586/14737140.6.7.1087 [Review].PubMed

76.

McDonough, W., Tran, N., Giese, A., Norman, S. A., & Berens, M. E. (1998). Altered gene expression in human astrocytoma cells selected for migration: I. Thromboxane synthase. Journal of Neuropathology and Experimental Neurology, 57(5), 449–455.PubMed

77.

Giese, A., Hagel, C., Kim, E. L., Zapf, S., Djawaheri, J., Berens, M. E., et al. (1999). Thromboxane synthase regulates the migratory phenotype of human glioma cells. Neuro-Oncology, 1(1), 3–13.PubMed

78.

Schauff, A. K., Kim, E. L., Leppert, J., Nadrowitz, R., Wuestenberg, R., Brockmann, M. A., et al. (2009). Inhibition of invasion-associated thromboxane synthase sensitizes experimental gliomas to gamma-radiation. Journal of Neuro-Oncology, 91(3), 241–249. doi:10.1007/s11060-008-9708-0.PubMed

79.

Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J., et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England Journal of Medicine, 352(10), 987–996. doi:10.1056/NEJMoa043330.PubMed

80.

Schmidt, N. O., Ziu, M., Cargioli, T., Westphal, M., Giese, A., Black, P. M., et al. (2010). Inhibition of thromboxane synthase activity improves glioblastoma response to alkylation chemotherapy. Translational Oncology, 3(1), 43–49.PubMed

81.

Hegi, M. E., Diserens, A. C., Gorlia, T., Hamou, M. F., de Tribolet, N., Weller, M., et al. (2005). MGMT gene silencing and benefit from temozolomide in glioblastoma. The New England Journal of Medicine, 352(10), 997–1003. doi:10.1056/NEJMoa043331.PubMed

82.

Gangwar, R., Mandhani, A., & Mittal, R. D. (2011). Functional polymorphisms of cyclooxygenase-2 (COX-2) gene and risk for urinary bladder cancer in North India. Surgery, 149(1), 126–134 [Comparative Study].PubMed

83.

Danon, A., Zenser, T. V., Thomasson, D. L., & Davis, B. B. (1986). Eicosanoid synthesis by cultured human urothelial cells: Potential role in bladder cancer. Cancer Research, 46(11), 5676–5681.PubMed

84.

Moussa, O., Riker, J. M., Klein, J., Fraig, M., Halushka, P. V., & Watson, D. K. (2008). Inhibition of thromboxane synthase activity modulates bladder cancer cell responses to chemotherapeutic agents. Oncogene, 27(1), 55–62. doi:10.1038/sj.onc.1210629.PubMed

85.

Moussa, O., Yordy, J. S., Abol-Enein, H., Sinha, D., Bissada, N. K., Halushka, P. V., et al. (2005). Prognostic and functional significance of thromboxane synthase gene overexpression in invasive bladder cancer. Cancer Research, 65(24), 11581–11587. doi:10.1158/0008-5472.can-05-1622.PubMed

86.

Moussa, O., Ashton, A. W., Fraig, M., Garrett-Mayer, E., Ghoneim, M. A., Halushka, P. V., et al. (2008). Novel role of thromboxane receptors beta isoform in bladder cancer pathogenesis. Cancer Research, 68(11), 4097–4104. doi:10.1158/0008-5472.can-07-6560.PubMed

87.

Patan, S. (2004). Vasculogenesis and angiogenesis. Cancer Treatment and Research, 117, 3–32.PubMed

88.

Ashton, A. W., Yokota, R., John, G., Zhao, S., Suadicani, S. O., Spray, D. C., et al. (1999). Inhibition of endothelial cell migration, intercellular communication, and vascular tube formation by thromboxane A(2). Journal of Biological Chemistry, 274(50), 35562–35570.PubMed

89.

Ashton, A. W., & Ware, J. A. (2004). Thromboxane A₂ receptor signaling inhibits vascular endothelial growth factor–induced endothelial cell differentiation and migration. Circulation Research, 95, 372–379.PubMed

90.

Ashton, A. W., Cheng, Y., Helisch, A., & Ware, J. A. (2004). Thromboxane A₂ receptor agonists antagonize the proangiogenic effects of fibroblast growth factor-2: role of receptor internalization, thrombospondin-1, and αvβ3. Circulation Research, 94, 735–742.PubMed

91.

Gao, Y., Yokota, R., Tang, S., Ashton, A. W., & Ware, J. A. (2000). Reversal of angiogenesis in vitro, induction of apoptosis, and inhibition of AKT phosphorylation in endothelial cells by thromboxane A(2). Circulation Research, 87(9), 739–745.PubMed

92.

Beauchamp, M. H., Martinez-Bermudez, A. K., Gobeil, F., Jr., Marrache, A. M., Hou, X., Speranza, G., et al. (2001). Role of thromboxane in retinal microvascular degeneration in oxygen-induced retinopathy. Journal of Applied Physiology, 90(6), 2279–2288.PubMed

93.

De La Cruz, J. P., Moreno, A., Ruiz-Ruiz, M. I., & Sanchez De La Cuesta, F. (2000). Effect of DT-TX 30, a combined thromboxane synthase inhibitor and thromboxane receptor antagonist, on retinal vascularity in experimental diabetes mellitus. Thrombosis Research, 97(3), 125–131.

94.

Zou, M. H., Shi, C., & Cohen, R. A. (2002). High glucose via peroxynitrite causes tyrosine nitration and inactivation of prostacyclin synthase that is associated with thromboxane/prostaglandin H(2) receptor-mediated apoptosis and adhesion molecule expression in cultured human aortic endothelial cells. Diabetes, 51(1), 198–203.PubMed

95.

Kishi, Y., & Numano, F. (1989). In vitro study of vascular endothelial injury by activated platelets and its prevention. Atherosclerosis, 76(2–3), 95–101.PubMed

96.

Pal, S., Wu, J., Murray, J. K., Gellman, S. H., Wozniak, M. A., Keely, P. J., et al. (2006). An antiangiogenic neurokinin-B/thromboxane A2 regulatory axis. The Journal of Cell Biology, 174(7), 1047–1058. doi:10.1083/jcb.200603152.PubMed

97.

Benndorf, R. A., Schwedhelm, E., Gnann, A., Taheri, R., Kom, G., Didié, M., et al. (2008). Isoprostanes inhibit vascular endothelial growth factor–induced endothelial cell migration, tube formation, and cardiac vessel sprouting in vitro, as well as angiogenesis in vivo via activation of the thromboxane A2 receptor. A potential link between oxidative stress and impaired angiogenesis. Circulation Research, 103, 1037–1046.PubMed

98.

Daniel, T. O., Liu, H., Morrow, J. D., Crews, B. C., & Marnett, L. J. (1999). Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Research, 59(18), 4574–4577.PubMed

99.

Sakurai, T., Tamura, K., & Kogo, H. (2005). Stimulatory effects of eicosanoids on ovarian angiogenesis in early luteal phase in cyclooxygenase-2 inhibitor-treated rats. European Journal of Pharmacology, 516(2), 158–164.PubMed

100.

de Leval, X., Dassesse, T., Dogne, J. M., Waltregny, D., Bellahcene, A., Benoit, V., et al. (2006). Evaluation of original dual thromboxane A2 modulators as antiangiogenic agents. Journal of Pharmacology and Experimental Therapeutics, 318(3), 1057–1067. doi:10.1124/jpet.106.101188.PubMed

101.

Rocca, B., Loeb, A. L., Strauss, J. F., 3rd, Vezza, R., Habib, A., Li, H., et al. (2000). Directed vascular expression of the thromboxane A2 receptor results in intrauterine growth retardation. Nature Medicine, 6(2), 219–221.PubMed

102.

Wilson, S. J., McGinley, K., Huang, A. J., & Smyth, E. M. (2007). Heterodimerization of the alpha and beta isoforms of the human thromboxane receptor enhances isoprostane signaling. Biochemical and Biophysical Research Communications, 352(2), 397–403.PubMed

103.

Parent, J. L., Labrecque, P., Orsini, M. J., & Benovic, J. L. (1999). Internalization of the TXA2 receptor alpha and beta isoforms. Role of the differentially spliced cooh terminus in agonist-promoted receptor internalization. Journal of Biological Chemistry, 274(13), 8941–8948.PubMed

104.

Parent, J. L., Labrecque, P., Driss Rochdi, M., & Benovic, J. L. (2001). Role of the differentially spliced carboxyl terminus in thromboxane A2 receptor trafficking: Identification of a distinct motif for tonic internalization. Journal of Biological Chemistry, 276(10), 7079–7085.PubMed

105.

Rochdi, M. D., Laroche, G., Dupre, E., Giguere, P., Lebel, A., Watier, V., et al. (2004). Nm23-H2 interacts with a G protein-coupled receptor to regulate its endocytosis through an Rac1-dependent mechanism. Journal of Biological Chemistry, 279(18), 18981–18989.PubMed

106.

Theriault, C., Rochdi, M. D., & Parent, J. L. (2004). Role of the Rab11-associated intracellular pool of receptors formed by constitutive endocytosis of the beta isoform of the thromboxane A2 receptor (TP beta). Biochemistry, 43(19), 5600–5607.PubMed

107.

Reid, H. M., Wikstrom, K., Kavanagh, D. J., Mulvaney, E. P., & Kinsella, B. T. (2011). Interaction of angio-associated migratory cell protein with the TPalpha and TPbeta isoforms of the human thromboxane A receptor. Cellular Signalling, 23(4), 700–717.PubMed

108.

Honn, K. V., Cicone, B., & Skoff, A. (1981). Prostacyclin: A potent antimetastatic agent. Science, 212(4500), 1270–1272.PubMed

109.

Menter, D. G., Onoda, J. M., Taylor, J. D., & Honn, K. V. (1984). Effects of prostacyclin on tumor cell-induced platelet aggregation. Cancer Research, 44(2), 450–456.PubMed

Title: The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis
Authors: Prasanna Ekambaram
Wanyu Lambiv
Rosanna Cazzolli
Anthony W. Ashton
Kenneth V. Honn
Publication date: 01-12-2011
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 3-4/2011
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-011-9297-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3-4/2011

15-Lipoxygenase-1 as a tumor suppressor gene in colon cancer: is the verdict in?

Dissecting the role of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in colon, breast, and lung carcinogenesis

Preface

Sphingolipids in cancer

The cytochrome P450 pathway in angiogenesis and endothelial cell biology

The role of the EP receptors for prostaglandin E2 in skin and skin cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer